Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2006 Nov-Dec;26(6B):4177-83.

Evaluation of cancer chemopreventive agents using clones derived from a human prostate cancer cell line.

Author information

1
Department of Radiation Oncology, Division of Oncology Research, University of Pennsylvania School of Medicine, 3620 Hamilton Walk, Philadelphia, PA 19104-6072, USA. jhware@mail.med.upenn.edu

Abstract

BACKGROUND:

The successful use of clonal selection through fluctuation analysis of human cancer cells as a means for studying tumor progression has been previously reported.

MATERIALS AND METHODS:

Three clones derived from a parental population of human prostate cancer (LNCaP) cells were selected based on proliferation, hormone sensitivity and anchorage-independent growth. The effects of five potential cancer preventive agents were evaluated using cell proliferation, anchorage-independent growth and apoptosis as end-points.

RESULTS:

Clone 21 cells, which represent a presumptive normal phenotype, were generally more sensitive than Clone 17 and Clone 6 cells, which represent a more malignant phenotype, to fluasterone, 7beta-HF, L-selenomethionine and troglitazone in assays for proliferation and/or apoptosis.

CONCLUSION:

The results confirm the efficacy of the above agents as cancer chemopreventive agents and support our contention that clonal selection of established human cancer cells provides a model to study the efficacy of chemopreventive agents.

PMID:
17201130
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center